Lightburn E, Morand J J, Meynard J B, Kraemer P, Chaudier B, Pages F, Garnotel E, Patte J H, Banzet S, Dampierre H, Lepage J, Morillon M, Boutin J P, Hovette P, Chouc C
Service de Dermatologie, HIA Laveran, 13998 Marseille-Armées, France.
Med Trop (Mars). 2003;63(1):35-44.
The purpose of this retrospective analysis was to evaluate the outcome of pentamidine isethionate treatment (4 mg/kg of Pentamidine by the intramuscular route on Days 1 and 3) of cutaneous leishmaniasis in 326 cases that occurred during an outbreak among French military personnel in French Guyana from 1998 to 1999. A great difference was found between the 205 patients treated in French Guyana (series G) and 32 patients treated at the Laveran Military Hospital in Marseille, France (series L). Failure rate, i.e. 25% in series L versus 5% in series G, was significantly correlated with the delay to treatment which was much longer in series L. Extensive rhabdomyolysis was observed in all cases tested: this side-effect has not been reported. Based on these findings and a review of the literature on pentamidine isethionate, the authors recommend prompt treatment using lower doses. Other treatment alternatives for American cutaneous leishmaniasis are also presented including two of the latest developments in the field, i.e., oral treatment using miltefosine and topical treatment using agents such as paromomycine.
这项回顾性分析的目的是评估1998年至1999年法属圭亚那法国军事人员爆发的皮肤利什曼病中326例患者接受乙磺半胱氨酸喷他脒治疗(第1天和第3天通过肌肉注射途径给予4mg/kg喷他脒)的结果。在法属圭亚那接受治疗的205例患者(G组)和在法国马赛拉韦朗军事医院接受治疗的32例患者(L组)之间发现了很大差异。失败率,即L组为25%,而G组为5%,与治疗延迟显著相关,L组的治疗延迟要长得多。在所有检测病例中均观察到广泛的横纹肌溶解:尚未报道过这种副作用。基于这些发现以及对乙磺半胱氨酸喷他脒文献的综述,作者建议使用较低剂量进行及时治疗。还介绍了美洲皮肤利什曼病的其他治疗选择,包括该领域的两项最新进展,即使用米替福新的口服治疗和使用诸如巴龙霉素等药物的局部治疗。